Exhibit 99.1 Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024 SEATTLE, April 25, 2024 -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024. "Accolade has built a rare healthcare services business at scale with consistently strong growth rates. Whether serving consumers, employers, health plans, or government entities, the core of our value proposition is making healthcare easier to access, navigate, and ...

ipopba Elevator Pitch Accolade, Inc. (NASDAQ:ACCD) shares are rated as a Buy. Business data provider GlobalData refers to ACCD as a "personalized healthcare advocacy company" that "reduces healthcare costs for employers and improves health and benefits for employees." I reviewed Accolade's financial performance for the third quarter of fiscal 2024 (September 1, 2023 to November 30, 2023) in my previous update written on January 10 this year. With the latest article, I analyze ACCD's recent corporate develop ...

Award recognizes the innovative blend of AI technology with an empathetic human approach to deliver exceptional healthcare experiences for membersSEATTLE, March 20, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced it has been named a winner of the Business Intelligence Group's Artificial Intelligence Excellence Awards program for its application of Natural Language Processing. This award recognizes companies leveraging AI technology to solve real-world problems. Accolade is one of the only ...

McDonald Harris assumes new role on Executive Leadership Team to deliver an exceptional employee experience and support the growth and development of its 2,400+ global workforceSEATTLE, March 19, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today the promotion of Kelsi McDonald Harris as Chief People Officer and Senior Vice President."Transforming healthcare in this country requires visionary human resources leaders who are willing to challenge the status quo," said Rajeev Singh, Chairman an ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state’s largest healthcare provider, to cease all in vitro fertilization (IVF) treatments. For state residents seeking IVF treatments or similar medical procedures, this development promises to have signifi ...

Accolade (ACCD) closed the last trading session at $12, gaining 7.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.07 indicates a 25.6% upside potential.The average comprises 14 short-term price targets ranging from a low of $12 to a high of $19, with a standard deviation of $2.06. While the lowest estimate indicates no increase from the current price level, the most optimist ...

Persistent earnings growth captivates almost everyone, from the top brass to research analysts. This is because earnings are a measure of the money a company is making.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in the stock price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-over-q ...

Kindbody partnership builds on Accolade's commitment to offer best-in-class women's health, fertility and family-forming capabilities for customers and membersSEATTLE, Jan. 23, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Kindbody, a technology-driven fertility clinic network and family-building benefits provider for employers, will join the company's Trusted Partner Ecosystem to offer Accolade customers comprehensive, clinically guided support and care throughout a member's ferti ...

Accolade (ACCD) closed the last trading session at $11.88, gaining 5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.07 indicates a 26.9% upside potential.The average comprises 14 short-term price targets ranging from a low of $12 to a high of $19, with a standard deviation of $2.06. While the lowest estimate indicates an increase of 1% from the current price level, the most o ...